The therapeutic approach to target the incretin system for the treatment of type 2 diabetes involves the use of GLP-1 agonists or DPP-4 inhibitors to increase the levels of endogenous GLP-1 (Cosentino et al., 2020)
Clement, S
Crucially, semaglutide and tirzepatide have extensive human clinical-trial data and regulatory approval for specific conditions, whereas 5-Amino-1MQ remains a research compound with preclinical data primarily from animal studies
Flamm G, Glinsmann W, Kritchevsky D, Prosky L, Roberfroid M
Having a clear plan makes switching from Tirzepatide to Retatrutide much safer
Why Chronic Inflammation Matters Chronic inflammation is now recognized as a central driver of nearly every chronic disease we fear most, including: Cardiovascular disease Diabetes and metabolic syndrome Autoimmune conditions Alzheimers and other neurodegenerative diseases Its also a major contributor to biological aging